Jennifer Doudna on CRISPR, AI, and Gene Editing's

Editor's note: The editor has requested this piece be re-assigned to Priya Sharma. Dorothy "Dot" Williams remains the author of record on this byline.

The Nobel Prize arrived in Jennifer Doudna's garden. Stockholm was locked down by the pandemic, so the Nobel Committee shipped the medal to Berkeley and presented it among her plants. It's a detail that lands differently once you've watched her Bloomberg interview with Emily Chang — because Doudna's garden is also where she thinks, where she resets, where she pulls weeds and finds the mental space to return to one of the most consequential scientific projects of the century.

The interview is worth your time not because Doudna is a cheerleader for her own technology — she's notably not — but because she's one of the few people alive with both the depth to explain what CRISPR actually is and the credibility to say, plainly, what it isn't yet.

What CRISPR Is, and Where It Came From

The origin story is stranger and more elegant than the headlines suggest. Doudna and her collaborator Emmanuelle Charpentier were studying how bacteria defend themselves against viruses. When a virus attacks a bacterium, the cell saves a fragment of the viral DNA, converts it into a kind of genetic GPS — guide RNA — and if that virus returns, a protein called Cas9 acts like molecular scissors, tracking down the invader and cutting it apart.

The leap Doudna and Charpentier made was recognizing that this GPS could be reprogrammed. You could point those scissors at any genomic sequence — including sequences in human cells. Editing DNA stopped being theoretical.

Since then, Doudna has built the Innovative Genomics Institute at UC Berkeley into something that's equal parts research lab and startup incubator. Thirty-one spinout companies. Nine billion dollars in combined valuation. More than 2,500 jobs, mostly in California. The pipeline from discovery to commercialization is, by design, the point.

The Gap That Patients Are Living In

Here is where Doudna is most honest and, frankly, most useful to listen to. The science has outrun the delivery mechanism.

The first approved CRISPR therapies — for conditions like sickle cell disease — require extracting a patient's cells, editing them outside the body, and reinfusing them. It works. Victoria Gray, the first American sickle cell patient treated with CRISPR, is doing well. But the process is grueling, expensive, and logistically enormous. It is not a scalable path to treating rare diseases at population level.

The frontier Doudna is most excited about is what researchers call in vivo delivery: getting CRISPR molecules directly into the body, to the right cells, where they do their job and then stop. That's the transition that would actually change the math on access and cost.

The cost question crystallizes around baby KJ — an infant treated at the Children's Hospital of Philadelphia in 2025, the first patient to receive a fully personalized CRISPR therapy, designed specifically for his genetic condition. He's walking now, climbing on furniture, apparently convinced he's the funniest person in any room. His treatment cost around $800,000, funded by a patchwork of public grants, academic collaboration, and philanthropy.

"It can't be a path that costs millions of dollars," Doudna told Chang. "It can't be a path that takes a huge army of people and time to achieve."

That's not pessimism. That's an engineering problem — and Doudna seems to understand the difference. She's looking at a two-to-three year horizon for continued breakthroughs, with the goal of expanding the number of medical centers that can deliver these therapies and driving down the manufacturing cost of the CRISPR molecules themselves.

The AI Question, Which Is Really Two Questions

Silicon Valley has a story it tells about AI and biomedicine. Larry Ellison has said AI will cure cancer in a 48-hour window. An OpenAI executive has floated the idea that if ChatGPT surfaces a drug discovery, OpenAI should get a cut of sales. The imagery is of a thousand AI grad students working around the clock, smarter than any human researcher.

Doudna's response to all of this is not contempt — it's something more grounding. "Biology's hard. That's all."

She is not dismissing AI as a tool. She sees genuine utility in AI's ability to process data, flag patterns, improve the efficiency of experimental design, and help scientists avoid redundant work. But she draws a line at the claim that AI is innovating — that it's generating genuinely new ideas that no human had before. "I'm not seeing chatbots in our own experience innovating," she said. "They can be helpful with summarizing data... but I'm not seeing chatbots coming up with a brand new idea for something that nobody else ever thought of."

She's careful not to foreclose the question permanently — "I never say never" on AGI — but she's not holding her breath. And her deeper point is structural: any AI model is only as good as the biological data it trains on, and right now, that data is insufficient for the complexity of human biology. "We're not going to be able to simulate our way to an understanding of the human body."

This is actually a different argument than the one AI skeptics usually make. It's not a claim that AI is overhyped in general. It's a specific claim about what AI needs to become useful in this domain — better training data, more biological complexity captured — and a description of where that work currently stands. Worth separating those two things before forming a view.

The Funding Floor Is Moving

The conversation about AI and CRISPR timelines exists against a backdrop that Doudna addresses directly: federal research funding in the United States is contracting. Over the past three years, NSF grants have dropped 24%. Roughly 25,000 scientists and staff — about 20% of the federal research workforce — have left government agencies. Doudna frames this in returns-on-investment terms: every dollar invested through the NIH generates roughly $2.50 in economic benefit. That's not a rounding error.

Her concern about China is specific and not alarmist in framing: at the same moment the U.S. is pulling back, China is increasing state investment in biotech. She thinks it's a real possibility that China surges ahead, at least initially. Whether that gap is permanent or recoverable depends entirely on decisions that are being made right now in appropriations committees, not laboratories.

The anti-vaccine and MAHA political currents add a separate layer of pressure. Doudna worked on RNA research that underpinned COVID vaccines. She calls the current moment "very dangerous" — pointing to measles outbreaks as evidence of what happens when science communication fails and public trust erodes. Her self-critique is pointed: the scientific community hasn't done a good enough job explaining to non-scientists why publicly funded research matters.

The Ethics That Haven't Been Settled

The question of CRISPR-edited human embryos is where Doudna is most careful and, perhaps intentionally, least conclusive. She has predicted we'll see CRISPR-edited babies within 25 years. The technology, she says, will eventually get there. The governance hasn't begun to catch up.

Her framework is pragmatic: some applications belong in a clearly defensible category — devastating diseases with well-understood genetic causes, where a targeted edit is clean and the benefit is obvious. Editing out sickle cell disease is one example. Other applications — selecting for height, eye color, intelligence — belong in a different category entirely, partly because those traits are controlled by thousands of genes interacting in ways scientists still don't fully understand, and partly because tweaking a few genes without knowing the downstream effects is not a trade-off anyone can currently evaluate with confidence.

"All the genes in our cells are interacting with each other in ways that we mostly aren't aware of and don't understand yet," she said. "If we tweak one gene or even a few, we can't always be sure what the outcome is going to be."

That's the scientific argument. The social and regulatory argument — who decides, who has access, who pays — she acknowledges remains almost entirely unanswered.

She's been called the moral compass of biotech. She admits she misses the quiet joy of pure discovery. The ambassador role her husband assigned her in the garden the morning after the Nobel arrived was not what she signed up for. She's doing it anyway, which is its own kind of answer to the question of what responsible science looks like when the stakes are this high.

The babies whose parents are sending her photographs — the ones living with conditions that CRISPR might one day treat — are not waiting on the ethics debate to resolve itself. Neither, it turns out, is the technology.

By Dorothy "Dot" Williams, Small Business & Entrepreneurship Correspondent, Buzzrag